Alumni

Everyone listed here completed a doctorate in our group and has since moved on. There are more completed doctorates, though: some, for example Fatima Marok and Christiane Dings, still work with us and are listed under Team. All dissertations are listed under Theses.

• Christina Kovar, doctorate 2025
  A tailored approach towards the right dose of dasatinib, (E)-clomiphene, imatinib, and infliximab leveraging physiologically based pharmacokinetic and population pharmacokinetic modeling
• Helena Loer, doctorate 2025
  Predicting complex drug interactions of CYP3A4, CYP3A5, and CYP2D6 substrates: Physiologically based pharmacokinetic modeling for individualized therapy
• Nina Scherer, doctorate 2025
  The power of mathematical modeling and simulation in cardiometabolic disorders: Personalized treatment optimization and disease trajectories
• Hannah Britz, doctorate 2024
  Physiologically based pharmacokinetic modeling of CYP3A4, CYP1A2 and transporter substrates, inhibitors and inducers for the prediction of drug-drug interactions
• Laura Fuhr, doctorate 2024
  Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
• Markus Müller, doctorate 2023
  Die vielfältigen Facetten der Arzneimitteltherapiesicherheit: Mittelbare und unmittelbare Ansatzpunkte zur Verbesserung der Arzneimitteltherapiesicherheit
• Denise Feick, doctorate 2022
  Impact of drug-gene-disease interactions and diurnal variation on exogenous and endogenous renal transporter substrates: a physiologically based pharmacokinetic modeling approach
• Lukas Kovar, doctorate 2022
  Physiologically based pharmacokinetic modeling providing insights into the pharmacokinetics of buprenorphine, fentanyl and nicotine in adult and pediatric patients
• Arthur Van De Vyver, doctorate 2022
  Quantitative approaches in support of the early development of T-cell redirecting therapies
• Jan-Georg Wojtyniak, doctorate 2021
  Model informed drug development and precision dosing for drug-drug-gene-interactions: applications of physiologically-based pharmacokinetic modeling
• Anna-Katharina Volz, doctorate 2021
  Modelling and simulation techniques to investigate pharmacokinetics, pharmacodynamics, and drug-drug interactions
• Dominik Lott, doctorate 2018
  Quantitative assessment of the effects of the selective S1P1 receptor modulator ponesimod using pharmacometric modeling and simulation
• Daniel Moj, doctorate 2018
  Translational physiologically-based pharmacokinetic (PBPK) modeling and simulation to support drug development and pharmacotherapy
• Melanie Titze, doctorate 2017
  Novel approaches for translational research in oncology: Pharmacometric modeling of oncolytic virus dynamics and a new tyrosine kinase inhibitor